(Q36716602)

15 August 2017

1 reference

title

Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. (English)

1 reference

15 August 2017

1 reference

Wadworth AN

1

1 reference

PubMed ID

1724637

15 August 2017

Goa KL

series ordinal

2

1 reference

15 August 2017

1 December 1991

1 reference

15 August 2017

1 reference

15 August 2017

42

1 reference

15 August 2017

1018-1060

1 reference

15 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199142060-00009

15 August 2017

0 references

cites work

Usual and unusual antibacterial effects of quinolones

1 reference

12 December 2020

Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin, but not by ofloxacin

1 reference

12 December 2020

In vitro and in vivo activity of NY-198, a new difluorinated quinolone

1 reference

12 December 2020

Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates

1 reference

12 December 2020

Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital

1 reference

12 December 2020

[Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].

1 reference

12 December 2020

4-quinolones inhibit biotransformation of caffeine

1 reference

12 December 2020

Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice

1 reference

12 December 2020

Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses

1 reference

12 December 2020

Bacterial resistance to fluoroquinolones

1 reference

12 December 2020

In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin

1 reference

12 December 2020

Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

1 reference

12 December 2020

Antibacterial and plasmid curing activity of lomefloxacin in vitro

1 reference

12 December 2020

In vitro activities of seven quinolone derivatives against Neisseria gonorrhoeae.

1 reference

12 December 2020

Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.

1 reference

12 December 2020

Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives

1 reference

12 December 2020

Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens

1 reference

12 December 2020

Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance

1 reference

12 December 2020

Comparative in vitro activity of lomefloxacin, a difluoro-quinolone

1 reference

12 December 2020

New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

1 reference

12 December 2020

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

1 reference

12 December 2020

Central nervous system toxicity of quinolones: human and animal findings

1 reference

12 December 2020

Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes

1 reference

12 December 2020

Reproductive studies of NY-198 in rats. II. Teratology study

1 reference

12 December 2020

Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites

1 reference

12 December 2020

Epidemiological and therapeutic study on gonorrheal infection--study on NY-198 (lomefloxacin) single administration therapy. Sapporo Clinical Research Group for STD

1 reference

12 December 2020

Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes

1 reference

12 December 2020

Pharmacokinetics and safety of lomefloxacin following multiple doses

1 reference

12 December 2020

Lomefloxacin activity against 2,813 clinical isolates: a collaborative study at three medical centers in Brazil.

1 reference

12 December 2020

In vitro activities of lomefloxacin, tetracycline, penicillin, spectinomycin, and ceftriaxone against Neisseria gonorrhoeae and Chlamydia trachomatis

1 reference

12 December 2020

Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin.

1 reference

12 December 2020

Mechanism of action of lomefloxacin

1 reference

12 December 2020

Kinetic interaction between theophylline and a newly developed quinolone, NY-198

1 reference

12 December 2020

Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections

1 reference

12 December 2020

Overview of postmarketing experience with ofloxacin in Germany

1 reference

12 December 2020

Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

1 reference

12 December 2020

In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents

1 reference

12 December 2020

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones

1 reference

12 December 2020

Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function

1 reference

12 December 2020

Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid

1 reference

12 December 2020

In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.

1 reference

12 December 2020

New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay

1 reference

12 December 2020

Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

[A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis].

1 reference

12 December 2020

Intraocular dynamic mode differences of new quinolone antibacterial agents between pigmented and albino rabbit eyes

1 reference

12 December 2020

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

1 reference

12 December 2020

A ten-laboratory study of lomefloxacin (NY-198 or SC 47111) antimicrobial activity in Argentina.

1 reference

12 December 2020

The possible mechanism of interaction between xanthines and quinolone

1 reference

12 December 2020

Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria

1 reference

12 December 2020

In vitro activity of lomefloxacin (SC 47111 or NY-198), a new quinolone antimicrobial, against clinical isolates of common pathogens

1 reference

12 December 2020

Intraprostatic distribution of lomefloxacin following multiple-dose administration

1 reference

12 December 2020

The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg.

1 reference

12 December 2020

Effect of lomefloxacin on the normal oral and intestinal microflora

1 reference

12 December 2020

Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

Enoxacin--a potent inhibitor of theophylline metabolism.

1 reference

12 December 2020

Antimicrobial effects of lomefloxacin in vitro

1 reference

12 December 2020

Epidemiological and therapeutic study on urethritis of male and cervicitis from viewpoint of STD--a study using NY-198. Sapporo Clinical Research Group for STD

1 reference

12 December 2020

Influence of lomefloxacin on the pharmacokinetics of theophylline

1 reference

12 December 2020

Fluoroquinolone antimicrobial agents

1 reference

12 December 2020

Antibiotic susceptibility and beta-lactamase production in clinical isolates of Enterobacter spp.

1 reference

12 December 2020

In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum

1 reference

12 December 2020

A simple isocratic high-pressure liquid chromatographic assay of quinolones in serum.

1 reference

12 December 2020

Mechanisms of Fluoroquinolone Resistance in Staphylococcus aureus

1 reference

12 December 2020

The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man

1 reference

12 December 2020

The influence of quinolone derivatives on theophylline clearance

1 reference

12 December 2020

Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers.

1 reference

12 December 2020

[In vitro evaluation of lomefloxacin]

1 reference

12 December 2020

In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones

1 reference

12 December 2020

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

Clinical effect of NY-198 (lomefloxacin) for sexually transmitted disease--bacteriological effect of U. urealyticum

1 reference

12 December 2020

Effect of lomefloxacin on theophylline pharmacokinetics

1 reference

12 December 2020

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

Activity of new quinolones against ciprofloxacin-resistant staphylococci

1 reference

12 December 2020

Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

1 reference

12 December 2020

Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days

1 reference

12 December 2020

High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes

1 reference

12 December 2020

Lomefloxacin (SC-47111 or NY-198). Comparative antimicrobial activity against 2002 clinical isolates from hospitals in Mexico City.

1 reference

12 December 2020

Ciprofloxacin-resistant Staphylococcus aureus

1 reference

12 December 2020

Penetration of lomefloxacin into human prostatic tissue

1 reference

12 December 2020

In vitro activity of tosufloxacin against bacterial enteric pathogens.

1 reference

12 December 2020

Antibacterial activity of fluoroquinolones in combination with zidovudine.

1 reference

12 December 2020

[Prostatic tissue and fluid levels of lomefloxacin (NY-198)]

1 reference

12 December 2020

Mechanisms of resistance to quinolones and clinical perspectives

1 reference

12 December 2020

In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains.

1 reference

12 December 2020

Pharmacokinetics and safety of single oral doses of lomefloxacin

1 reference

12 December 2020

Pharmacokinetics of lomefloxacin in renally compromised patients

1 reference

12 December 2020

Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline

1 reference

12 December 2020

Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus

1 reference

12 December 2020

Clinical uses of nalidixic acid analogues: the fluoroquinolones

1 reference

12 December 2020

In vitro activity of lomefloxacin (NY-198 or SC 47111).

1 reference

12 December 2020

Antibacterial activity of lomefloxacin

1 reference

12 December 2020

Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.

1 reference

12 December 2020

A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology

1 reference

12 December 2020

Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.

1 reference

12 December 2020

[Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis]

1 reference

12 December 2020

Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa

1 reference

12 December 2020

Effect of food on absorption of lomefloxacin

1 reference

12 December 2020

Meta-analysis of quinolone-theophylline interactions

1 reference

12 December 2020

In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea

1 reference

12 December 2020

In vitro activity of lomefloxacin (SC 47111 or NY-198) against Chlamydia trachomatis strains

1 reference

12 December 2020

Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli

1 reference

12 December 2020

Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.

1 reference

12 December 2020

The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities

1 reference

12 December 2020

Lack of effective bactericidal activity of new quinolones against Brucella spp.

1 reference

12 December 2020

Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli

1 reference

12 December 2020

In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains

1 reference

12 December 2020

Comparative in vitro activity of lomefloxacin and other antimicrobials against 597 microorganisms causing bacteremia.

1 reference

12 December 2020

Lack of interaction between lomefloxacin and caffeine in normal volunteers

1 reference

12 December 2020

Entry of the new quinolone antibacterial agents of ofloxacin and NY-198 into the central nervous system in rats

1 reference

12 December 2020

Rapid HPLC assay of fluoroquinolones in clinical specimens

1 reference

12 December 2020

[Chemotherapy for biliary tract infection (XXXIII). Tissue concentration of NY-198 in gallbladder, biliary excretion and clinical effects].

1 reference

12 December 2020

Evaluation of in vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, Enterobacteriaceae, and Pseudomonas aeruginosa.

1 reference

12 December 2020

The comparative activity of lomefloxacin (SC-47111, NY-198) and other orally absorbable agents against Haemophilus influenzae and Branhamella catarrhalis

1 reference

12 December 2020

Concentrations of oral lomefloxacin in serum and bronchial mucosa

1 reference

12 December 2020

Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of orally administered lomefloxacin

1 reference

12 December 2020

In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.

1 reference

12 December 2020

Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.

1 reference

12 December 2020

In vitro activity of lomefloxacin (SC 47111 or NY-198) against isolates of Legionella spp.

1 reference

12 December 2020

The 4-quinolone antibiotics: past, present, and future

1 reference

12 December 2020

Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses

1 reference

12 December 2020

Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1.

1 reference

12 December 2020

In-vitro activity of lomefloxacin (SC-47111) and other quinolones

1 reference

12 December 2020

Studies on the emergence of resistance to lomefloxacin in vitro.

1 reference

12 December 2020

Efficacy of NY-198 against experimental Legionnaires disease

1 reference

12 December 2020

10.2165/00003495-199142060-00009

Identifiers

DOI

1 reference

PubMed ID

1724637

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

1724637